中国的药物监管者接受Pimicotinib申请,这是对罕见肿瘤的一种新治疗。 China's drug regulator accepts application for pimicotinib, a new treatment for a rare tumor.

以上海为基地的Abbisko治疗技术公司宣布,中国的NMPA已经接受为Pimicotinib(CSF-1R)使用的新药物申请,这是治疗Tenosynovial Giant细胞肿瘤(TGCT)的CSF-1R抑制剂。 Shanghai-based Abbisko Therapeutics announced that China's NMPA has accepted the New Drug Application for pimicotinib, a CSF-1R inhibitor for treating Tenosynovial Giant Cell Tumor (TGCT). 临床试验显示,患者结果有显著改善。 Clinical trials showed significant improvements in patient outcomes. 该药物获得优先审查,预计将加快其批准程序。 The drug received Priority Review, expected to expedite its approval process. Merck拥有全球商业皮米科蒂尼b权利。 Merck has global commercial rights to pimicotinib.